 incid neuropathi patient ovarian cancer cisplatin consecut trial total patient ovarian cancer combin hexamethylmelamin cyclophosphamid methotrex chemotherapeut regimen cisplatin drug respect neurotox patient elig median follow-up surviv month neurotox grade sever patient cisplatin-contain regimen non-cisplatin-contain regimen sever neurotox cisplatin-tr patient neurotoxicity-fre surviv cumul dose cisplatin addit effect hexamethylmelamin incid sever neurotox patient year incid cisplatin neuropathi prognost variabl age intern feder gynecolog obstetr figo stage perform statu other high-risk subgroup consist factor neurotox total dose cisplatin